天麻素治疗神经衰弱有效性的Meta分析

Meta-Analysis of Efficacy of Gastrodin in the Treatment of Neurasthenia

摘要: 目的：评价天麻素治疗神经衰弱的临床治疗效果。方法：检索中国知网、维普、万方、中国生物医学文献数据库和PubMed，搜集天麻素治疗神经衰弱的临床随机对照试验(RCT)，对照组采用阿普唑仑单药治疗，实验组在对照组基础上加用天麻素，截止时间至2023年3月31日，数据处理使用RevMan 5.4软件。结果：共纳入16项RCTs，1548例患者。Meta分析结果显示，天麻素双联治疗组的治疗总有效率显著高于单药治疗组[OR = 4.31, 95%CI (3.12, 5.95), P < 0.05]；天麻素双联治疗组的汉密尔顿焦虑量表(HAMA) [MD = −7.31, 95%CI (−10.14, −4.12), P < 0.05]、汉密尔顿抑郁量表(HAMD) [SMD = −6.35, 95%CI (−8.81, −3.89), P < 0.05]、匹兹堡睡眠质量指数(PSAI) [MD = −2.22, 95%CI (−2.64, −1.81), P < 0.05]评分均显著低于单药治疗组。结论：天麻素可显著改善患者焦虑、抑郁评分，提高患者睡眠质量，提高神经衰弱的临床治疗效果。

Abstract: Objective: To evaluate the clinical efficacy of gastrodin in the treatment of neurasthenia. Methods: CNKI, VIP, Wanfang, CBM, and PubMed databases were searched to collect clinical RCTs of gastrodin in the treatment of neurasthenia until March 31, 2023. Data were processed using Review Manager 5.4 software. Results: A total of 1548 patients were enrolled in 16 RCTs. The control group included 761 patients who received alprazolam monotherapy, while the experimental group included 787 patients who received additional gastrodin to the control group. Meta-analysis results showed that the total effective rate of gastrodin dual therapy group was higher than that of alprazolam mono-therapy group [OR = 4.31, 95%CI (3.12, 5.95, P < 0.05)]. The scores of Hamilton Anxiety Scale (HAMA) [MD = −7.33, 95%CI (−10.54, −4.21), P < 0.05], Hamilton Depression Scale (HAMD) [SMD = −2.06, 95%CI (−2.99, −1.13), P < 0.05] and Pittsburgh Sleep quality Index [SMD = −2.89, 95%CI (−3.12, −2.66), P < 0.05] in the combined treatment group were significantly lower than those in the monotherapy group. Conclusion: Gastrodin can significantly improve the clinical treatment effect of neurasthenia, improve the symptoms of anxiety and depression, and improve the quality of sleep.